Messiah University

Mosaic
Biology Educator Scholarship

Biological Sciences

2018

Efficiency of a Malaria Reactive Test-And-Treat Program in
Southern Zambia: A Prospective, Observational Study
D-F Molly
H. Hamapumbu
J. Lubinda
M. Musonda
B. Katowa

See next page for additional authors
Follow this and additional works at: https://mosaic.messiah.edu/bio_ed
Part of the Biology Commons

Permanent URL: https://mosaic.messiah.edu/bio_ed/163
Recommended Citation
Molly, D-F; Hamapumbu, H.; Lubinda, J.; Musonda, M.; Katowa, B.; Searle, K. M.; Kobayashi, T.; Shields, T.
M.; Stevenson, J.; Thuma, Philip; and Moss, W. J., "Efficiency of a Malaria Reactive Test-And-Treat
Program in Southern Zambia: A Prospective, Observational Study" (2018). Biology Educator Scholarship.
163.
https://mosaic.messiah.edu/bio_ed/163

Sharpening Intellect | Deepening Christian Faith | Inspiring Action
Messiah University is a Christian university of the liberal and applied arts and sciences. Our mission is to educate
men and women toward maturity of intellect, character and Christian faith in preparation for lives of service,
leadership and reconciliation in church and society.
www.Messiah.edu

One University Ave. | Mechanicsburg PA 17055

Authors
D-F Molly, H. Hamapumbu, J. Lubinda, M. Musonda, B. Katowa, K. M. Searle, T. Kobayashi, T. M. Shields, J.
Stevenson, Philip Thuma, and W. J. Moss

This article is available at Mosaic: https://mosaic.messiah.edu/bio_ed/163

Am. J. Trop. Med. Hyg., 98(5), 2018, pp. 1382–1388
doi:10.4269/ajtmh.17-0865
Copyright © 2018 by The American Society of Tropical Medicine and Hygiene
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Trust, Choma District, Zambia; 3Department of Epidemiology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland;
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Abstract. To improve malaria surveillance and achieve elimination, the Zambian National Malaria Elimination Program
implemented a reactive test-and-treat program in Southern Province in 2013 in which individuals with rapid diagnostic test (RDT)–conﬁrmed malaria are followed-up at their home within 1 week of diagnosis. Individuals present at the
index case household and those residing within 140 m of the index case are tested with an RDT and treated with
artemether–lumefantrine if positive. This study evaluated the efﬁciency of this reactive test-and-treat strategy by characterizing infected individuals missed by the RDT and the current screening radius. The radius was expanded to 250 m,
and a quantitative polymerase chain reaction (qPCR) test was performed on dried blood spot specimens. From January
2015 through March 2016, 145 index cases were identiﬁed at health centers and health posts. A total of 3,333 individuals
residing in 525 households were screened. Excluding index cases, the parasite prevalence was 1.1% by RDT (33 positives
of 3,016 participants) and 2.4% by qPCR (73 positives of 3,016 participants). Of the qPCR-positive cases, 62% of 73
individuals tested negative by RDT. Approximately half of the infected individuals resided within the index case household (58% of RDT-positive individuals and 48% of qPCR-positive individuals). The low sensitivity of the RDT and the high
proportion of secondary cases within the index case household decreased the efﬁciency of this reactive test-and-treat
strategy. Reactive focal drug administration in index case households would be a more efﬁcient approach to treating
infected individuals associated with a symptomatic case.

treated without testing.14,15 Advantages of focal drug administration are that infected individuals who may otherwise
be missed with a low-sensitivity RDT are treated, and the
strategy does not increase the demand for RDTs.14,15 The
disadvantage is that individuals not infected at the time of visit
are exposed to antimalarial drugs. However, individuals residing in index case households are at the highest risk and
administration of antimalarial drugs may provide chemoprophylaxis, particularly with the longer acting dihydroartemisinin–
piperaquine combination.
The National Malaria Elimination Program of the Government of Zambia created a stepped sequence of interventions
to achieve malaria elimination.16–18 Designated as Steps A
through E, these interventions are to be implemented in succession depending on the parasite prevalence and case burden at health facilities.17,18 Step D consists of training volunteer
community health workers to perform community case management and reactive test-and-treat within 140 m of index
case households. Step D is implemented in low-transmission
communities in which the parasite prevalence is approximately 1% and an average of 10 or fewer malaria cases present to a healthcare facility per week.17 In 2013, Step D
activities were implemented through a phased implementation plan in selected districts in Southern Province, Zambia,
with the goals of improving surveillance and interrupting
transmission.16,19 As part of this study, the reactive test-andtreat radius was expanded to include all households within
250 m of the index case household and PCR-based diagnostic
testing was added. This allowed us to evaluate the efﬁciency
of Step D in identifying and treating infected individuals by
including molecular detection of Plasmodium falciparum to
identify infected individuals with low-level parasitemia and by
extending the screening radius from 140 to 250 m.

INTRODUCTION
As malaria transmission declines, the proportion of the total
infected population comprised of asymptomatic, chronically
infected individuals with low parasite densities increases.1–4
Some chronically infected individuals are capable of transmitting malaria parasites in areas with competent vectors.1,3,4
Several strategies have been developed to identify and treat
these individuals. Focal or mass drug administration relies
on treating high-risk groups or entire populations on the
assumption that malaria rapid diagnostic tests (RDTs) are insufﬁciently sensitive to identify infected individuals with lowlevel parasitemia.5,6 Active case detection, in contrast, involves
screening individuals for malaria with RDTs within a deﬁned
geographic area (“hot spots”) or high-risk populations (“hot
pops”) and treating those who test positive. Active case detection, and focal and mass drug administration, aim to eliminate parasites from chronically infected individuals, facilitating
the interruption of local transmission.7
One method of active case detection involves reactive
case detection, which leverages the underlying spatial and
temporal clustering of malaria transmission.8–10 Reactive case
detection includes reactive test-and-treat and reactive focal
drug administration. For reactive test-and-treat, residents in
the home of a symptomatic index case and those in neighboring households within a deﬁned radius are screened with
an RDT and offered treatment if positive.11–13 For reactive
focal drug administration, individuals residing within an index
case household, and potentially neighboring households, are
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METHODS
Study site. The study was conducted in the rural catchment
area of Macha Hospital in Choma District, Southern Province,
Zambia, 70 km from the nearest town of Choma. The area has
a tropical savannah climate with distinct wet and dry seasons.
Malaria transmission is highest during the single rainy season
from November through April, with Anopheles arabiensis as
the primary vector.20,21 The hospital catchment area is populated by villagers living in small, scattered homesteads,
comprised of single or multiple houses typically with extended
family. The parasite prevalence as measured by active surveillance using a Pfhrp2 RDT declined over the past decade,
from 9.2% in 2008 to less than 1% in 2013.22 Artemisinin
combination therapy with artemether–lumefantrine was introduced as ﬁrst-line antimalarial therapy in Zambia in 2002 and
into the study area in 2004.23,24 Long-lasting insecticide-treated
nets (LLINs) were widely distributed in the study area in 2007,
and more than 11,000 LLINs were distributed from nine health
centers in the catchment area of Macha Hospital in 2012, with
additional LLINs distributed in 2014.20 Insecticide-treated net
ownership was estimated at 83% in the study area in 2013.16
Study population. The study population consisted of individuals residing within 250 m of an index case household.
Symptomatic individuals diagnosed with malaria by RDT and
eligible for reactive case detection were considered index
cases. When an individual sought care at a healthcare facility
and tested positive for malaria by RDT, their eligibility for
follow-up with reactive test-and-treat was determined. Community health workers excluded individuals with a reported
travel history as these cases were presumed to be imported.
Travel was deﬁned as staying overnight in a place outside
their home district within the previous month. Rapid diagnostic test–positive individuals who had not traveled were
eligible for reactive test-and-treat. Eligible index cases were to
be followed up within 1 week of diagnosis.
As part of the study, health workers sent a short message
service text message to the study team based at Macha Research Trust, located at Macha Hospital, within 1 week of
identifying an index case to plan the reactive test-and-treat
activities. A study team member accompanied the health
worker to the index case household for a notiﬁcation visit, at
which time the head of household and other residents were
informed that the health worker and study team would return
the following day to perform the informed consent procedures, administer a questionnaire, and collect a ﬁngerprick
blood sample. Through the informed consent process, residents of index and neighboring households could refuse
participation in the study activities.
Global positioning system (GPS) coordinates of the index
houses were collected during the notiﬁcation visit and were
subsequently mapped using ArcGIS v.10 (ERSI, Redlands,
CA). A QuickBird high-resolution satellite image of the study
area obtained in 2011 was imported into ArcGIS and all
households within a radius of 250 m of the index house were
identiﬁed. A printed image of the index case household and
eligible secondary households was provided to the study
team to guide enrollment.
Study procedures. Study enrollment began in January
2015, and continued through March 2016. Residents of
households within 250 m of an index case household were
eligible for the study and written informed consent was

obtained from adults and parental permission from caregivers
of children who agreed to participate. Questionnaires were
administered to collect information on age, gender, recent
history of malaria, signs and symptoms of malaria (deﬁned as
the presence of fever with either chills or headache), recent
antimalarial use, bed net use, and socioeconomic status.
Fingerprick blood samples were collected from participants
for a P. falciparum HRP2 RDT (SD Bioline, Gyeonggi-do, Republic of Korea) and dried blood spots (Whatman 903™ Protein Saver Card; Sigma-Aldrich, Piscataway, NJ). Individuals
who tested positive by RDT (other than the index case who
was presumed to have been treated at the health center
or health post) were offered treatment with artemether/
lumefantrine in accordance with the Zambian Ministry of
Health guidelines. The study was approved by the Tropical
Diseases Research Center Ethics Review Committee and
the Institutional Review Board at the Johns Hopkins
Bloomberg School of Public Health. Local government ofﬁcials were informed of the study purpose and procedures
before data collection and local community acceptance
was sought.
Laboratory procedures. DNA was extracted from dried
blood spots using a previously described Chelex extraction
protocol.21,25 Quantitative polymerase chain reaction was
performed to detect the presence of the P. falciparum cytochrome b gene (Pfcytb). Using standard genomic DNA dilution
series and ﬁlter paper spotted with cultured parasites (NF54),
the limit of detection was determined to be 1 parasite/μL.
Primers were designed to detect the presence of Pfcytb and
ampliﬁcation was detected by ﬂuorescence signal of SYBR®
Green. Each reaction contained 5 μL of DNA template, 5 μL of
SYBR Green PCR Master Mix (ThermoFisher, Waltham, MA),
and 200 nM of forward primer (59 CCT GAT AAT GCT ATC GTA
39) and reverse primer (59 TAA TAC AAT TAC TAA ACC AGC
39). All qPCR-positive samples were evaluated on a 4% agarose gel to conﬁrm the product size of the amplicon. Only
samples conﬁrmed by both qPCR and gel electrophoresis
were considered qPCR positive.
Statistical analysis. The primary outcomes of interest were
the prevalence of individuals who were RDT positive (detected
through reactive test-and-treat) and those positive by qPCR
but negative by RDT (missed by reactive test-and-treat) within
the index case household, within 140 m of the index case
household, and between 140 and 250 m of the index case
household (missed with the current screening radius). The
individuals who tested positive during the rainy season (November through March) were compared with those positive
during the dry season (April through October). Index cases
were excluded from the analyses. Differences in proportions
were tested using Fisher’s exact test. Statistical analyses were
performed using STATA version 14 (StataCorp LP, College
Station, TX).
RESULTS
Study households and participants. From January 2015
through March 2016, 145 index cases residing in 125 index
case households were identiﬁed as eligible for reactive case
detection, and the study team was notiﬁed by a health worker
(Figure 1). Through reactive case detection, 146 households
were identiﬁed within 140 m of the index case households,
and, as part of this study, 251 households were identiﬁed
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between 140 and 250 m from the index case households.
Thus, 24% of study households were index case households,
28% were within 140 m of the index case household, and 48%
were located between 140 and 250 m of the index case
household.
During the reactive case detection, 841 residents of the 125
index case households and 671 individuals residing in the 146
households within 140 m of the index case household were
enrolled. An additional 1,480 individuals residing in the 251
households between 140 and 250 m of the index case
household were enrolled as part of the study. Of the study
participants, 28% (excluding index cases) lived within index
case households, 22% resided in households within 140 m of
the index case household, and 50% resided in households
within 140–250 m from the index case household. The
median age of study participants was 12 years (interquartile
range: 6, 27) and 54% were female (Table 1). Household
GPS coordinates were available for 2,992 of the 3,016 individuals with complete RDT and PCR data.
Parasite prevalence. Excluding index cases, a total of
3,188 individuals were tested for malaria by RDT and qPCR,
and data on both RDT and qPCR status were available for
3,016 (95%) of these participants (Table 1). Of those 3,016
participants, the prevalence of malaria was 1.1% by RDT (33
positives of 3,016 participants) and 2.4% by qPCR (73 positives of 3,016 participants). Of the 525 households visited,
29 (6%) had at least one non-index case that tested positive
by RDT and 56 (11%) households had at least one non-index

case positive by qPCR. Thirty-ﬁve households (7%) had at
least one individual who was qPCR positive but RDT negative. Parasite prevalence by RDT and qPCR did not vary by
season, despite the seasonal transmission pattern in southern
Zambia.
Efﬁciency of the reactive test-and-treat radius. Of the
RDT-positive individuals, 58% lived in the index case household, 12% lived within 140 m of the index case household, and
30% lived between 140 and 250 m of the index case household (Table 2, Figure 2). Thus, most RDT-positive individuals
resided within the index case households and only a small
proportion resided within the 140-m screening radius. No
differences were observed in the proportion of individuals who
were RDT positive in houses within 140 m (0.6%) compared
with those residing 140–250 m (0.7%) of the index case
household (P = 0.99) (Table 2, Figure 2A). At the household
level, 59% of households with an RDT-positive resident were
index case households.
Efﬁciency of reactive test-and-treat using an RDT. More
than half of infected individuals (55% of those who were
qPCR positive) were negative by RDT, indicating that most
infected individuals would not be detected by a reactive testand-treat strategy using a standard sensitivity RDT in this
low-transmission setting (Table 1). At the household level,
40% of households with a resident who was RDT negative but
qPCR positive were index case households, 14% were
households located within 140 m of the index case household,
and 46% were households located between 140 and 250 m of

FIGURE 1. Map of index case households included in the reactive test-and-treat program. This ﬁgure appears in color at www.ajtmh.org.
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TABLE 1
Baseline characteristics of study participants
Total (%)
Median age in years (IQR)
Female (%)
Malaria symptoms*
Yes (%)
No (%)
Sleeps under a bed net†
Yes (%)
No (%)

All participants

RDT+

RDT−

PCR+

PCR−

PCR+ RDT−

PCR− RDT−

3,016
12 (6–27)
1,624 (53.8)

33 (1.1)
12 (7–15)
17 (51.5)

2,983 (98.9)
12 (6–27)
1,593 (53.7)

73 (2.4)
11.5 (6–21.5)
35 (48.6)

2,943 (97.6)
12 (6–27)
1,575 (53.8)

45 (1.5)
11.5 (5–23.5)
20 (44.5)

2,938 (98.5)
12 (6–27)
1,573 (53.9)

392 (13.4)
2,531 (86.5)

11 (33.3)
22 (66.7)

379 (13.2)
2,492 (86.7)

21 (30.4)
48 (69.6)

369 (13.0)
2,466 (87.0)

11 (26.8)
30 (73.2)

368 (13.0)
2,462 (87.0)

1,527 (53.5)
1,325 (46.5)

14 (45.2)
17 (54.8)

1,503 (53.6)
1,299 (46.4)

36 (51.4)
34 (48.6)

1,481 (53.6)
1,282 (46.4)

27 (61.4)
17 (38.6)

1,476 (53.5)
1,282 (46.5)

PCR = polymerase chain reaction; RDT = rapid diagnostic test.
* Data on malaria symptoms, deﬁned as fever with the presence of chills or headache, available for 2,923 individuals.
† Bed net data available for 2,852 individuals.

the index case household (Table 2). At the individual level,
40% of all individuals who were RDT negative but qPCR
positive lived within the index case household, 13% lived
within 140 m of the index case household, and 47% lived in
households between 140 and 250 m from the index case
household, outside the current screening radius (Table 2,
Figure 3). No statistically signiﬁcant differences were observed in the proportion of individuals who were RDT negative
but qPCR positive in houses within 140 m (0.9%) compared
with those residing 140–250 m (1.4%) of the index case
household (P = 0.45) (Table 2, Figure 3A).
DISCUSSION
The efﬁciency of a reactive test-and-treat strategy was
evaluated in a low-transmission setting in southern Zambia by
extending the existing screening radius from 140 to 250 m and
using qPCR to detect RDT-negative, infected individuals.
Overall, the sensitivity of the RDT was 45% compared with
qPCR. Thus, more than half of infected individuals were
missed using a standard-sensitivity RDT for screening in this
low-transmission setting. The highest proportion of RDTpositive individuals resided within index case households.
The proportion of infected individuals detected by either RDT
or qPCR did not differ between individuals residing outside
the index case household, that is, within 140 m or from 140 to
250 m of the index case household. These infected individuals
may largely represent a background prevalence of asymptomatic, chronically infected individuals rather than individuals
infected through local transmission associated with the index
case. These ﬁndings suggest that reactive focal drug

administration in the index case household may be a more
efﬁcient strategy to treat infected individuals than reactive
test-and-treat in this low-transmission setting. Among the
73 infected individuals detected using qPCR, 29% resided
within 140 m of the index case household and were RDT
positive, and thus would have been detected and treated by
the current test-and-treat strategy. By contrast, 48% of the 73
infected individuals detected using qPCR resided within an
index case household and would have been treated through
focal drug administration in the index case household alone.
However, neither reactive focal drug administration in the index case household nor reactive case detection in a 140-m
radius will identify and treat all infected individuals.
These ﬁndings are consistent with other assessments of
reactive test-and-treat programs in which this strategy was
shown to be an inefﬁcient method of identifying infected individuals in low-transmission settings.26 Studies conducted in
Zambia, Senegal, and Swaziland found that the number of
tested individuals to identify one infected individual ranged
from 37 to 250.11,12,27 In our study area, a mean of 90 RDTnegative residents were tested for each RDT-positive individual identiﬁed and a mean of 66 qPCR-negative residents
were tested for each qPCR-positive, RDT-negative individual
identiﬁed. A mean of 24 qPCR-negative residents of index
case households were tested for each qPCR-positive, RDTnegative individual identiﬁed within an index case household.
The high number of RDT-negative individuals tested for
each RDT-positive individual identiﬁed provides further evidence that in low-transmission settings reactive test-andtreat using a standard sensitivity RDT is not efﬁcient.
Interestingly, the sensitivity of the PfHRP2 RDT was higher in

TABLE 2
Parasite prevalence by RDT and PCR for study participants and households, by distance from the index case household
Index case household

Individuals
Households

N
841
125

Individuals
Households

841
125

Individuals
Households

822
125

Individuals
Households

806
125

RDT+
2.3%
13.6%
PCR+
4.2%
21.6%
PCR+/RDT−
2.2%
11.2%
PCR−/RDT+
0.3%
2.4%

RDT−
97.7%
86.4%
PCR−
95.8%
78.4%
PCR−
97.8%
88.8%
PCR−/RDT−
99.7%
98.4%

PCR = polymerase chain reaction; RDT = rapid diagnostic test.

Within 140 m of index case household

N
671
146
671
146
667
146
661
146

RDT+
0.6%
2.7%
PCR+
1.5%
6.2%
PCR+/RDT−
0.9%
3.4%
PCR−/RDT+
0%
0%

RDT−
99.4%
97.3%
PCR−
98.5%
92.8%
PCR−
99.0%
96.6%
PCR−/RDT−
100%
100%

140–250 m from index case household

N
1,480
251
1,480
251
1,470
251
1,452
251

RDT+
0.7%
3.2%
PCR+
1.9%
8.0%
PCR+/RDT−
1.4%
6.0%
PCR−/RDT+
0.2%
0.4%

RDT−
99.3%
96.8%
PCR−
98.1%
92.0%
PCR−
98.6%
94.0%
PCR−/RDT−
99.8%
99.6%
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FIGURE 2. Proportion of study participants who tested positive by rapid diagnostic test (RDT) within each household distance category (A) and
proportion all RDT-positive individuals (N = 33) living at each household distance (B).

comparison with qPCR when used for reactive case detection
(45%) than active case detection (17%) in the same community, perhaps reﬂecting higher levels of parasitemia associated with recent focal transmission around symptomatic
index cases.25
The low sensitivity of the PfHRP2 RDT for screening
asymptomatic or minimally symptomatic residents during
household surveys has spurned interest in the development
of higher sensitivity RDTs or ﬁeld-deployable molecular
assays.28,29 An ultrasensitive PfHRP2 RDT was recently
shown to have a 10-fold lower limit of detection for HRP2
compared with a standard RDT, with a sensitivity of 84%
compared with quantitative real-time-PCR in Uganda but
only 44% in Myanmar where transmission intensity is

lower.30 In a low-transmission setting such as southern
Zambia, where levels of parasitemia can be low in asymptomatic individuals, a similar ultrasensitive RDT is likely to
have a low sensitivity as it did in Myanmar.25 An additional
challenge to the use of PfHRP2 RDTs is the spread of the
Pfhrp2 gene deletions in sub-Saharan Africa.31 Although
Pfhrp2 deletions have not yet been reported in Zambia,
they have been identiﬁed in the neighboring Democratic Republic of Congo.32
There are several limitations to this study. First, the crosssectional study design did not allow for observations of the
natural history of malaria in study participants such that,
for example, RDT-negative, qPCR-positive individuals may
have been recently infected and thus did not yet develop

FIGURE 3. Proportion of study participants who were rapid diagnostic test (RDT) negative but quantitative polymerase chain reaction (qPCR)
positive within each household distance category (A) and proportion of RDT-negative but qPCR-positive participants (N = 44) living at each
household distance (B).

EFFICIENCY OF MALARIA-REACTIVE TEST-AND-TREAT IN ZAMBIA

sufﬁcient parasitemia to test positive by RDT or become
symptomatic. Second, we did not attempt to identify infection
with non-falciparum malaria. Plasmodium malariae has
been identiﬁed in the study area but the prevalence is low
and infection frequently coexists with P. falciparum.25
Last, not all household members were present during the
study visits. Nonparticipation of households and individual
residents is an inherent challenge to reactive test-andtreat strategies. 33
The low sensitivity of current RDTs and the high proportion
of secondary cases within index case households lowered
the efﬁciency of a reactive test-and-treat strategy in a lowtransmission setting in southern Zambia. Reactive focal drug
administration in index case households, in which all individuals within index case households are treated without testing,
appears to be a more efﬁcient approach to treating infected
individuals associated with a symptomatic case and would
greatly reduce the number of RDTs needed in such lowtransmission settings.
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